Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,229 recruiting studies in this area right now.
By phase
- Not applicable3,142
- Phase 21,065
- Phase 1822
- Phase 1/Phase 2446
- Phase 3423
- Phase 4237
- Phase 2/Phase 394
Top conditions
- Multiple Sclerosis341
- Multiple Myeloma332
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis142
- Type 1 Diabetes133
- Atopic Dermatitis128
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia123
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Rheumatoid Arthritis (RA)65
- Leukemia64
- Acute Myeloid Leukemia62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris70
- M.D. Anderson Cancer Center63
- Novartis Pharmaceuticals63
- AstraZeneca57
- City of Hope Medical Center47
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California492
- Maryland196
- Alabama176
- Florida143
- Arizona141
- New York123
- Massachusetts119
- Texas117
- Illinois82
- Colorado77
Recruiting studies6,229 total
- NCT04638790RecruitingPhase 3
First treatment chemotherapy study for newly diagnosed Hodgkin lymphoma
This trial studies the best first chemotherapy approach for people newly diagnosed with classical Hodgkin lymphoma. It may help improve outcomes by comparing how treatment is given in routine care settings in Russia.
Mumbai, Opd-81 Main Building, Dr. E Borges Road, Parel 400012Ages 18–50 - NCT04644016RecruitingPhase 2
Cord blood transplant for children and young adults with blood cancers
This Phase 2 trial studies using a cord blood transplant after finding it is risky enough that standard treatment may not be sufficient. It may help certain children and young adults with specific leukemia, lymphoma, and some non-cancer blood/immune or inherited disorders who do not have a well-matched donor available in time.
New York, New YorkAges Up to 21 years - NCT04645199Recruiting
Long-term follow-up study for blood and bone marrow diseases
This study is collecting long-term follow-up information from people diagnosed with certain blood and bone marrow conditions. It may help doctors understand what happens over time and improve future care, but you’re mainly contributing data rather than receiving a new treatment.
Tianjin, Tianjin MunicipalityAges Any age - NCT04645511Recruiting
Balloon treatment for long-term or repeat maxillary sinusitis
This study tests whether balloon sinuplasty works better or more efficiently for people with long-lasting or repeatedly returning inflammation in the maxillary sinuses (side sinuses near your cheeks). It focuses on people who did not improve with the usual nose spray (topical steroid) or who meet specific “recurrent” episode patterns.
TampereAges 18–69 - NCT04648046RecruitingPhase 1/Phase 2
CAR-T cell treatment for HIV infection
This early-phase study tests whether CAR-T cells (immune cells modified to recognize HIV) can help control HIV. You may be asked to briefly pause HIV medicines to see how well the treatment controls the virus.
Sacramento, CaliforniaAges 18–65 - NCT04650321RecruitingPhase 4
Home infusions of ocrelizumab for some people with MS
This study looks at giving ocrelizumab treatments at home instead of in a clinic for people with MS. It’s meant to see if this approach is practical and acceptable while you keep receiving a medicine your MS doctor thinks you should continue.
Centennial, ColoradoAges 18–55 - NCT04653324Recruiting
Registry for people with diagnosed food allergies
This registry aims to collect information from people who already have a diagnosed food allergy. Joining may help researchers better understand food allergy patterns and needs.
McLean, VirginiaAges Any age - NCT04653610Recruiting
Study immune signals in untreated HIV using extra samples
This study looks at tiny cell “messengers” in blood and stool to understand how HIV behaves before and after starting treatment. You may be eligible if you have untreated HIV (or you’re a healthy volunteer) and can commit to many sample visits, including long-term storage for 20 years.
Ghent, Oost-VlaanderenAges 18–65 - NCT04654923Recruiting
Survey of allergic reactions around anesthesia
This study collects information about people who had an allergic-type reaction around surgery or anesthesia. It aims to understand how often these reactions happen and to improve future care. You may be able to join if your reaction fits the time window and you agree to use your records.
StrasbourgAges 7 years+ - NCT04657861RecruitingEarly Phase 1
BCMA/TACI CAR-T for relapsed or refractory multiple myeloma
This early-phase study tests a CAR-T cell treatment made to target BCMA and TACI proteins in multiple myeloma. It may help people whose myeloma has come back or did not respond to prior treatments, especially after certain prior therapies.
Hangzhou, ZhejiangAges 18–75 - NCT04657783Recruiting
French cohort study of people with type 1 diabetes
This study follows people with type 1 diabetes in France to better understand the condition over time. It may help researchers improve future care, especially for how type 1 diabetes starts and is managed from early diagnosis onward.
ParisAges 6–100 - NCT04658303Recruiting
Study of immune and metabolism changes in in-transit melanoma
This trial studies how the immune system and body metabolism change in people with in-transit melanoma (melanoma spread to nearby skin). It aims to understand what’s happening in these lesions and how that information could guide better treatment.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT04660487Recruiting
How diet carbs affect GVHD after bone marrow transplant
This study looks at whether certain types of gut carbohydrates (called FODMAPs) are linked to graft-versus-host disease (GVHD) after a bone marrow transplant. It may help doctors understand how diet could influence symptoms and outcomes for people with specific blood cancers.
Suzhou, JiangsuAges 18–60 - NCT04662294RecruitingEarly Phase 1
CD70-targeted CAR T therapy for CD70-positive blood cancers
This trial tests a customized immune-cell treatment (CAR T) that targets CD70 on cancer cells in certain blood cancers. It may help people whose disease has returned or did not respond to standard treatments.
Hangzhou, ZhejiangAges Any age - NCT04662723RecruitingPhase 4
Personalized treatment for IgA kidney disease
This trial tests whether choosing treatment based on your personal kidney findings can improve outcomes in adults with IgA nephropathy (IgAN). It may help by matching therapy to the type and severity of kidney damage seen on biopsy.
Bari, BAAges 18 years+ - NCT04664179RecruitingPhase 1
EBV immune-cell treatment for EBV-positive lymphoma
This Phase 1 study tests an immune-cell therapy made to recognize EBV (a common virus) in people whose lymphoma contains EBV. It may help control EBV-driven cancers, especially when standard treatment isn’t working or can’t be used.
Houston, TexasAges Any age - NCT04663204RecruitingPhase 2
Sparsentan study for IgA kidney disease in adults
This Phase 2 trial studies whether sparsentan is safe and can slow down kidney damage in adults with IgA nephropathy (IgAN). Participants may receive sparsentan to improve kidney-related measures such as protein in the urine.
Cambridge, EnglandAges 18 years+ - NCT04667026Recruiting
Study of people living with HIV on treatment
This is an observational study that follows people with HIV who are taking HIV medicines (antiretroviral therapy). It may help researchers understand how treatment is going and what factors relate to doing well on therapy.
Guangzhou, GuangdongAges 14 years+ - NCT04669171RecruitingPhase 1/Phase 2
Vaccine treatment for slow-growing lymphoma, alone or combined
This trial tests a new vaccine medicine (EO2463) to treat indolent non-Hodgkin lymphoma (slow-growing lymphoma), either by itself or with other treatment. It may help your immune system recognize and attack lymphoma cells.
Boston, MassachusettsAges 18 years+ - NCT04670029RecruitingPhase 3
Testing an APA program to improve outcomes in large B-cell lymphoma
This Phase 3 trial studies whether an APA program (an added supportive program during care) can improve event-free survival for people with diffuse large B-cell lymphoma. It may help by supporting patients during standard first-line treatment so they do better over time.
BesançonAges 65 years+ - NCT04670874Recruiting
Quality of life in people with cutaneous lymphoma
This study asks people with cutaneous lymphoma to fill out a questionnaire about quality of life. The goal is to better understand how this illness affects day-to-day life and comfort.
Duarte, CaliforniaAges 18 years+ - NCT04672733Recruiting
Switch from IVIg to Hizentra for CIDP nerve inflammation
This study tests Hizentra® as an alternative to IV immunoglobulin (IVIg) for adults with CIDP, a condition where the immune system damages the nerves. You may be able to switch to Hizentra if your current IVIg treatment is keeping your CIDP stable and you can switch safely.
AmiensAges 18 years+ - NCT04675918Recruiting
Registry for children’s in-hospital cardiac arrest
This study collects information about children (from 1 month to 18 years) who have a cardiac arrest while in the hospital. The goal is to better understand what happens during these emergencies and improve care in the future.
MadridAges 1 month–18 years - NCT04678401RecruitingPhase 1
Trial tests transplant using a half-matched donor for high-risk leukemia
This Phase 1 trial tests a special bone marrow transplant using a related “half-matched” donor (haploidentical), without a specific immune-suppressing medicine (“IS-free”). It’s for adults with certain high-risk AML or MDS to see if this approach can improve control of the disease while tracking safety.
Boston, MassachusettsAges 18–75
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,229 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,721 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.